Literature DB >> 16873382

Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR).

B Tremey1, B Szekely, S Schlumberger, D François, N Liu, K Sievert, M Fischler.   

Abstract

BACKGROUND: Activated clotting time (ACT) is currently used to monitor high concentrations of heparin anticoagulation. A new instrument, the Hemochron Jr Signature device, has been specifically designed to measure ACT in low-range heparin plasma concentrations (ACT-LR). The purpose of this study was to compare ACT-LR with anti-Xa activity in patients receiving low-dose i.v. heparin during vascular surgery.
METHODS: Thirty patients, undergoing arterial vascular surgery, were included in the study and received unfractionated heparin (initial dose 50 u kg(-1)). One hundred and thirty-two pairs of blood samples were simultaneously collected during surgery to determine ACT-LR and anti-Xa activity. Pearson correlation, Kappa test, ROC curve and a specific clinical interpretation of the correlation were performed.
RESULTS: ACT-LR ranged from 68 to 380 s, anti-Xa activity from 0 to 1.45 u ml(-1). We observed a strong correlation between anti-Xa activity and ACT-LR (r(2)=0.87; P<0.0001). Accuracy of ACT-LR was good for anti-Xa activity up to 0.6 u ml(-1) (Kappa, 0.94; accuracy, 97%) and 0.8 u ml(-1) (Kappa, 0.79; accuracy, 90%), and poor for anti-Xa activity above 1 u ml(-1) (Kappa, 0.59). A clinical interpretation of the correlation graph found 98% of measured ACT-LR values to be accurate.
CONCLUSION: Hemochron Jr Signature provides measurements of ACT-LR, which are accurate for monitoring heparin anticoagulation at anti-Xa activity below 0.8 u ml(-1).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873382     DOI: 10.1093/bja/ael194

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

Review 1.  [Portable coagulometer devices in the monitoring and control of oral anticoagulation therapy: a systematic review].

Authors:  Javier Caballero-Villarraso; Román Villegas-Portero; Fernando Rodríguez-Cantalejo
Journal:  Aten Primaria       Date:  2010-10-30       Impact factor: 1.137

2.  Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.

Authors:  Anne-Céline Martin; Sarah Lessire; Isabelle Leblanc; Anne-Sophie Dincq; Ivan Philip; Isabelle Gouin-Thibault; Anne Godier
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

Review 3.  Anaesthesia for endovascular repair of ruptured abdominal aortic aneurysms.

Authors:  K Berry; J Gudgeon; J Taylor
Journal:  BJA Educ       Date:  2022-03-11

4.  Monitoring unfractionated heparin in pediatric patients with congenital heart disease having cardiac catheterization or cardiac surgery.

Authors:  G G Kim; S El Rouby; J Thompson; A Gupta; J Williams; D R Jobes
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.